Salarius Pharmaceuticals Inc
SLRX0.685USD
+0.014+2.09%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
647.07KMarket Cap
LossP/E TTM
More Details of Salarius Pharmaceuticals Inc Company
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Company's lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader being developed for the treatment of Non-Hodgkins Lymphoma. SP-3164 is a small molecule protein degrader, and seclidemstat (SP-2577) is a small molecule inhibitor. SP-3164 is a next-generation cereblon-binding molecular glue (MG). SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold.
Salarius Pharmaceuticals Inc Info
Ticker SymbolSLRX
Company nameSalarius Pharmaceuticals Inc
IPO dateJan 29, 2015
CEOPierce (Frederick E)
Number of employees2
Security typeOrdinary Share
Fiscal year-endJan 29
Address2450 Holcombe Blvd Ste J-608
CityHOUSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code77021-2041
Phone13467720346
Websitehttps://salariuspharma.com/
Ticker SymbolSLRX
IPO dateJan 29, 2015
CEOPierce (Frederick E)
Company Executives of Salarius Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Mark J. Rosenblum, CPA
Mr. Mark J. Rosenblum, CPA
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
20.18K
+10989.01%
Mr. Frederick E. (Rick) Pierce, II
Mr. Frederick E. (Rick) Pierce, II
Chief Executive Officer, Director
Chief Executive Officer, Director
16.67K
--
Mr. David J. Arthur
Mr. David J. Arthur
Director
Director
409.00
--
Mr. Arnold C. Hanish, CPA
Mr. Arnold C. Hanish, CPA
Independent Director
Independent Director
27.00
--
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Independent Director
Independent Director
25.00
--
Ms. Tess Burleson, CPA
Ms. Tess Burleson, CPA
Independent Director
Independent Director
23.00
--
Dr. Paul I. Lammers, M.D.
Dr. Paul I. Lammers, M.D.
Independent Director
Independent Director
--
--
Dr. William K. McVicar, Ph.D.
Dr. William K. McVicar, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Maureen McEnroe
Ms. Maureen McEnroe
IR Contact Officer
IR Contact Officer
--
--
Mr. Peter Marschel
Mr. Peter Marschel
Chief Business Officer
Chief Business Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Mark J. Rosenblum, CPA
Mr. Mark J. Rosenblum, CPA
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
20.18K
+10989.01%
Mr. Frederick E. (Rick) Pierce, II
Mr. Frederick E. (Rick) Pierce, II
Chief Executive Officer, Director
Chief Executive Officer, Director
16.67K
--
Mr. David J. Arthur
Mr. David J. Arthur
Director
Director
409.00
--
Mr. Arnold C. Hanish, CPA
Mr. Arnold C. Hanish, CPA
Independent Director
Independent Director
27.00
--
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Independent Director
Independent Director
25.00
--
Ms. Tess Burleson, CPA
Ms. Tess Burleson, CPA
Independent Director
Independent Director
23.00
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Heights Capital Management, Inc.
5.12%
Rosenblum (Mark J)
0.34%
Pierce (Frederick E)
0.28%
Other
94.25%
Shareholders
Shareholders
Proportion
Heights Capital Management, Inc.
5.12%
Rosenblum (Mark J)
0.34%
Pierce (Frederick E)
0.28%
Other
94.25%
Shareholder Types
Shareholders
Proportion
Investment Advisor
5.13%
Individual Investor
0.64%
Other
94.23%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
20
8.11K
1.59%
+1.28K
2025Q2
31
110.17K
7.08%
+40.05K
2025Q1
32
106.28K
5.17%
+40.01K
2024Q4
31
57.08K
3.76%
+6.17K
2024Q3
40
41.64K
3.78%
-25.65K
2024Q2
43
62.50K
7.79%
+8.97K
2024Q1
48
60.52K
8.08%
+3.79K
2023Q4
55
98.98K
22.39%
+24.12K
2023Q3
60
83.57K
23.57%
+12.31K
2023Q2
67
67.48K
20.55%
-4.45K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Rosenblum (Mark J)
182.00
0.04%
--
--
Sep 19, 2025
Arthur (David J)
409.00
0.08%
--
--
Sep 19, 2025
Horizon Kinetics LLC
259.00
0.05%
--
--
Aug 31, 2025
The Vanguard Group, Inc.
83.00
0.02%
--
--
Aug 31, 2025
Osaic Holdings, Inc.
4.00
0%
-7.00
-63.64%
Jun 30, 2025
UBS Financial Services, Inc.
1.21K
0.24%
-1.04K
-46.36%
Jun 30, 2025
Hanish (Arnold C)
27.00
0.01%
--
--
Sep 19, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 14, 2025
Merger
15→1
Jun 12, 2024
Merger
8→1
Jun 12, 2024
Merger
8→1
Jun 12, 2024
Merger
8→1
Jun 12, 2024
Merger
8→1
Oct 14, 2022
Merger
25→1
Date
Type
Ratio
Aug 14, 2025
Merger
15→1
Jun 12, 2024
Merger
8→1
Jun 12, 2024
Merger
8→1
Jun 12, 2024
Merger
8→1
Jun 12, 2024
Merger
8→1
Oct 14, 2022
Merger
25→1
Oct 14, 2022
Merger
25→1
Oct 14, 2022
Merger
25→1
Oct 14, 2022
Merger
25→1
FAQs
Who are the top five shareholders of Salarius Pharmaceuticals Inc?
The top five shareholders of Salarius Pharmaceuticals Inc are:
Rosenblum (Mark J) holds 182.00 shares, accounting for 0.04% of the total shares.
Arthur (David J) holds 409.00 shares, accounting for 0.08% of the total shares.
Horizon Kinetics LLC holds 259.00 shares, accounting for 0.05% of the total shares.
The Vanguard Group, Inc. holds 83.00 shares, accounting for 0.02% of the total shares.
Osaic Holdings, Inc. holds 4.00 shares, accounting for 0.00% of the total shares.
Rosenblum (Mark J) holds 182.00 shares, accounting for 0.04% of the total shares.
Arthur (David J) holds 409.00 shares, accounting for 0.08% of the total shares.
Horizon Kinetics LLC holds 259.00 shares, accounting for 0.05% of the total shares.
The Vanguard Group, Inc. holds 83.00 shares, accounting for 0.02% of the total shares.
Osaic Holdings, Inc. holds 4.00 shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Salarius Pharmaceuticals Inc?
The top three shareholder types of Salarius Pharmaceuticals Inc are:
Heights Capital Management, Inc.
Rosenblum (Mark J)
Pierce (Frederick E)
Heights Capital Management, Inc.
Rosenblum (Mark J)
Pierce (Frederick E)
How many institutions hold shares of Salarius Pharmaceuticals Inc (SLRX)?
As of 2025Q3, 20 institutions hold shares of Salarius Pharmaceuticals Inc, with a combined market value of approximately 8.11K, accounting for 1.59% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -5.49%.
What is the biggest source of revenue for Salarius Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for Salarius Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
